# BOREAS (NCT03662126)

> KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

No report yet. It can be ordered.

- Indication: myelofibrosis relapsed or refractory to JAK inhibitor treatment

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03662126
- Phase: PHASE2, PHASE3
- Status: UNKNOWN
- Sponsor: Kartos Therapeutics, Inc.
- Conditions: Primary Myelofibrosis (PMF); Post-Polycythemia Vera MF (Post-PV-MF); Post-Essential Thrombocythemia MF (Post-ET-MF)
- Interventions: KRT-232; Best Available Therapy (BAT)
- Enrollment: 385
- Primary outcome: (Part A Only) Spleen Volume Reduction (SVR)
- Primary outcome: (Part B Only) Spleen Volume Reduction (SVR)

## Indexed commentary on BOREAS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 13
- Podcasts: 12
- X threads: 4
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=boreas-nct03662126

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03662126", "email": "<work email>"}; the inbox owner confirms by the emailed link.